Bronstein, Gewirtz & Grossman LLC Urges Capricor Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against Capricor Therapeutics, Inc. alleging that the company made materially false and misleading statements regarding its Deramiocel drug candidate. The complaint claims Capricor changed its statistical analysis plan without FDA agreement and failed to disclose the significant risk that the FDA would reject the Biologics License Application, putting regulatory approval for treating Duchenne muscular dystrophy in jeopardy.